{
  "subset": "indication",
  "disease": "Atypical haemolytic uraemic syndrome",
  "relation": "indication",
  "gold_drugs": [
    "eculizumab"
  ],
  "seeds_initial": [
    "Eculizumab",
    "Ravulizumab",
    "Plasma exchange",
    "Complement Inhibitors",
    "Supportive care",
    "Acanthopanax",
    "Tolvaptan",
    "Corticosteroids",
    "Immunosuppressants",
    "Antiplatelet drugs",
    "Cytokine inhibitors",
    "Anticoagulants"
  ],
  "seed_history": [
    [
      "Eculizumab",
      "Ravulizumab",
      "Plasma exchange",
      "Complement Inhibitors",
      "Supportive care",
      "Acanthopanax",
      "Tolvaptan",
      "Corticosteroids",
      "Immunosuppressants",
      "Antiplatelet drugs",
      "Cytokine inhibitors",
      "Anticoagulants"
    ],
    [
      "Eculizumab",
      "Ravulizumab",
      "Avacopan",
      "C5 Inhibitor",
      "Corticosteroids",
      "Plasmapheresis",
      "Cyclosporine",
      "Rituximab",
      "Mycophenolate mofetil",
      "Tacrolimus",
      "Complement inhibitors",
      "Eltrombopag"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_eculizumab",
          "name": "Eculizumab"
        },
        "score": 0.69,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "Eculizumab通过补体抑制作用于aHUS",
          "支持性证据可确认短期疗效"
        ],
        "caveats": [
          "长期疗效尚未确立"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_ravulizumab",
          "name": "Ravulizumab"
        },
        "score": 0.67,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "Ravulizumab作为补体抑制剂与Eculizumab具有相似机制"
        ],
        "caveats": [
          "潜在相同风险路线导致治疗效果不确定"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_avacopan",
          "name": "Avacopan"
        },
        "score": 0.64,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "Avacopan通过调节补体途径作用于该疾病"
        ],
        "caveats": [
          "缺乏长期跟踪效果的研究"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Eculizumab与Ravulizumab通过补体抑制途径作用于aHUS",
          "reason": "已知机制与有效性支持"
        }
      ],
      "remaining_gaps": [
        "各假设的长期疗效和安全性数据尚需补充"
      ]
    },
    "seed_retrospective": {
      "batches": [],
      "lessons": [
        "需优先考虑具有明确机制并有支持性循证的候选药物"
      ]
    },
    "prompt_patches": [],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Atypical haemolytic uraemic syndrome'. Return only names.\n\n# Heuristics:\n- When Atypical haemolytic uraemic syndrome: then 重点关注补体抑制与免疫机制的相互作用"
}